These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631 [TBL] [Abstract][Full Text] [Related]
12. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1. Shahid KR; Amrami KK; Esther RJ; Lowe VJ; Spinner RJ J Surg Orthop Adv; 2011; 20(2):132-5. PubMed ID: 21838076 [TBL] [Abstract][Full Text] [Related]
13. Malignant Peripheral Nerve Sheath Tumor With Bilateral Adrenal Metastases: Role of 18F-FDG PET/CT in Response Assessment to Tyrosine Kinase Inhibitor and Liposomal Doxorubicin. Tripathy S; Passah A; Singhal A; Prashanth A; Kumar R Clin Nucl Med; 2019 Jun; 44(6):494-495. PubMed ID: 30889004 [TBL] [Abstract][Full Text] [Related]
14. Teaching NeuroImages: Intracranial malignant triton tumor: An uncommon location of a rare tumor. Dias AB; Cambruzzi E; Giugno CS; Miranda de Curtis R; Faria do Amaral LL; Lenhardt R Neurology; 2019 Mar; 92(12):e1401-e1402. PubMed ID: 30886081 [No Abstract] [Full Text] [Related]
15. Potential usefulness of 18F-2-fluoro-deoxy-D-glucose positron emission tomography in cervical compressive myelopathy. Baba H; Uchida K; Sadato N; Yonekura Y; Kamoto Y; Maezawa Y; Furusawa N; Abe Y Spine (Phila Pa 1976); 1999 Jul; 24(14):1449-54. PubMed ID: 10423790 [TBL] [Abstract][Full Text] [Related]
17. (18)F-FDG PET/CT in an unusual case of cardiac plexiform neurofibromatosis. D'souza MM; Sondhi P; D'souza P; Sharma R; Jaimini A; Pandey S; Mondal A; Tripathi RP Clin Nucl Med; 2015 Jun; 40(6):529-30. PubMed ID: 25706790 [TBL] [Abstract][Full Text] [Related]
18. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. Bredella MA; Caputo GR; Steinbach LS AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489 [TBL] [Abstract][Full Text] [Related]
19. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas. Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. Lucas JD; O'Doherty MJ; Wong JC; Bingham JB; McKee PH; Fletcher CD; Smith MA J Bone Joint Surg Br; 1998 May; 80(3):441-7. PubMed ID: 9619933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]